Contineum Therapeutics (CTNM) Operating Leases (2023 - 2025)
Historic Operating Leases for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $4.0 million.
- Contineum Therapeutics' Operating Leases changed N/A to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2024, which is 435092.59% up from last year.
- Per Contineum Therapeutics' latest filing, its Operating Leases stood at $4.0 million for Q3 2025.
- Contineum Therapeutics' Operating Leases' 5-year high stood at $4.8 million during Q4 2024, with a 5-year trough of $108000.0 in Q4 2023.
- Moreover, its 3-year median value for Operating Leases was $4.0 million (2025), whereas its average is $2.6 million.
- In the last 5 years, Contineum Therapeutics' Operating Leases surged by 435092.59% in 2024 and then soared by 369115.04% in 2025.
- Contineum Therapeutics' Operating Leases (Quarter) stood at $108000.0 in 2023, then soared by 4350.93% to $4.8 million in 2024, then fell by 16.46% to $4.0 million in 2025.
- Its Operating Leases stands at $4.0 million for Q3 2025, versus $4.3 million for Q2 2025 and $4.5 million for Q1 2025.